
### **VOLUME 1**

#### **JULY 2023**





# NEWSLETTER



# INSIDE THIS ISSUE

- Updates
- Forthcoming events
- Kick-Off Meeting
- Recruited DOCTORAL Candidates introduction.
- Communication & dissemination.

The ISOBIOTICS project is a European interdisciplinary and intersectorial Doctoral Network that aims at training 10 + 1 Ph.D. students (Doctoral Candidates, DCs) for devising new approaches to isotopic labeling of biological drugs. The project is granted for 4 years (Maximum EU contribution of 2.7 M€). It involves 14 Partners in 6 European countries and the United Kingdom as follows:

- 5 Beneficiaries (including 2 Big Pharma);
- 1 Associated Beneficiary (UK Beneficiary);
- 8 Associated Partners.

More Information on CORDIS



**ISOBIOTICS** 

**ISOBIOTICS** Website

www.isobiotics-project.org/





#### >>> ISOBIOTICS UPDATES

- All ISOBIOTICS Doctoral Candidates have been recruited.
  - 22 JULY 2023
- Shivani Utekar, the ISOBIOTICS Project Manager, has joined the Central Management Team and is now operational.
  - -9 MAY 2023

### >>> FORTHCOMING EVENTS

VOL 1 JULY 2023

- 1st ISOBIOTICS Check Meeting (date and location yet to be fixed by the Project Officer)
- 1st ISOBIOTICS Meeting & Training (Saclay/Versailles, date depending on the check meeting)
- ISOBIOTICS will participate in the IIS International Meeting in Gothenburg.
   (JUNE, 2025)

#### >>> ISOBIOTICS UPDATES

 To date, 7 deliverables (1.1-1.5 and 6.1-6.2) have been submitted.

#### - JULY 2023

 Amendment request was evaluated and accepted by by REA.

#### - 12 JUNE 2023

- Due to the initiation of an amendment procedure
   (January 19th 2023) with the replacement of a Beneficiary and the introduction of new Associated Partners, the signature of the Consortium Agreement has been delayed.
- SANOFI changed the associated academic entity for PhD awarding from LMU to IQS in Spain.
- Termination of CHEMPRECISE in Portual led to its replacement by IMM in Portugal; FFUL will be the associated academic entity for PhD awarding.
- Introduction of AstraZeneca UK (Dr. Bala NN Rao Attili) as associated partner

# NOMINATION OF THE ADVISORY BOARD / YOUNG FELLOW ADVISOR KICK-OFF MEETING 27 MARCH 2023

The mission of the AB is to review the scientific advances of the ISOBIOTICS project, to advise the ISOBIOTICS Partners about the general scientific strategy and to follow-up all aspects of the project's implementation.

The Young Fellow Advisor (YFA) is supposed to help Doctoral Candidates (DCs) for integrating the Consortium smoothly, to advise them and to reassure them in order to allow them initiating their thesis work in the best conditions.

The Advisory Board including Prof. Chris WILLIS, Prof. Olof SOLIN and Dr.Pascal GEORGE was unanimously elected.



Dr. Malvika SARDANA-SHEKHAR was unanimously elected as YFA of the ISOBIOTICS project.



## **ISOBIOTICS** KICK OFF MEETING, PARIS, FRANCE



🙎 Villa Lemons, 5 Imp. Mousset, 75012 Paris

#### 27 MARCH 2023



From the left to the right: D. Guglielminotti, D. Audisio, A. Sib, V. Derdau, C. Dugave, C. Elmore, B. Kuhnast, B. Davis, F. Taran, S. Specklin, G. Pieters

Coordinator Dr Christophe **DUGAVE** reminded all attendees of the general rules for project implementation as specified in the Grant Agreement and the project-specific procedures for administrative and scientific implementation research, training, networking, secondments.

All Beneficiaries Representatives elected the Supervisory Board, the Advisory Board, and the Young Fellow Advisor

The Open Research, Ethics, and Communication aspects were especially highlighted.

The particular case of RFI as an Associated Partner granted by the UK was also discussed.

All DC's Supervisors explained the updated thesis research projects, except DC7's Supervisor who was absent.



The ISOBIOTICS Kick-Off Meeting took place on March 27 in the 12th district of Paris in the absence of the Project Manager who had not requested yet for the work permit.


Only 11 of 15 Partners Representatives the meeting face-to-face, attended attended remotely & 3 couldn't attend the meeting.


According to general demand, the meeting was reduced to 1 single day (instead of 1.5) due to strikes in France and resulting transportation issues. The meeting gathered CEA, LMU, IMM (teleconference), SANOFI, and AZ Representatives.



🧘 Le Train Bleu

After the official meeting ended, participants visited atypical Paris streets and stopped for a beer in a bar for an informal discussion which was continued around a gala dinner.





Rafael Jiménez Rioboo (ES)

### **ISOBIOTICS**



Justin Alich (DE)

**VOL 1 JULY 2023** 

Alfonso Fumanal Idocin (ES)







Marc San José GRACIA (ES)

sanofi

AstraZeneca 2

Malamatenia Papavasileiou (EL)











Esther Calviño Sanlés (ES)



Marine GUINGAND (FR)

HORIZON EUROPE - MSCA - DN- 2021 #101072780

01-02-2023 to 31-01-2027

#### ANIKA SCHICK, ASTRAZENECA GOTHENBURG/ AARHUS UNIVERSITY

supervised by Dr. Chad ELMORE

I think being part of the ISOBIOTICS project and its interdisciplinary doctoral network will be a valuable experience. The project recognizes the importance of developing new radiolabeling strategies for biological drugs. From the perspective of a PhD student, the possibility of being trained in an international and interdisciplinary network with knowledge exchange in the frame of workshops and secondments is very exciting!



#### MARINE GUINGAND, (ROSALIND FRANKLIN INSTITUTE) RFI/ UNIVERSITY OF OXFORD

supervised by **Prof Benjamin Davis** 



As a pharmacist, I'm fully aware of the importance of developing new radiolabeling approaches, both in terms of diagnosis and treatment. Within the ISOBIOTIC project, the fact that academia and private industries collaborate is a key factor in order to develop the most valuable strategies for patients. Also, as a student, having a multidisciplinary environment across Europe is a great opportunity to learn from different backgrounds and nationalities to improve our soft and scientific skills, as well as communication.

#### ESTHER CALVIÑO SANLÉS, IMM LISBON/FFUL

supervised by Prof Gonçalo Bernardes

I consider that radiolabeling of biomolecules requires a highly interdisciplinary approach. ISOBIOTICS benefits from an interdisciplinary perspective thanks to the 14 partners which are involved in the project. Moreover, working in close proximity with industry will allow the practical implementation of the research findings.



#### ELISA MARTINELLI, SANOFI AVENTIS DEUTSCHLAND GMBH/ UNIVERSITY OF ROSTOCK

supervised by Dr. Volver Derdau



The main strength of ISOBIOTICS is to be a dynamic platform that aims at fostering discussions and ideas among its members and between academia and industry, addressing a topic that is of increasing relevance to the scientific community. Moreover, this project gives a unique possibility to provide its members with comprehensive training and to promote scientific growth through structured exchanges of ideas and knowledge on isotope chemistry.

#### **JUSTIN ALICH, CEA / UNIVERSITY OF PARIS-SACLAY**

supervised by Dr. Davide AUDISIO

What is outstanding about the ISOBIOTICS project is the strong interdisciplinary network and the international exchange, which encourages people to think beyond their core profession and beyond borders.



# STRENGTHS OF THE |SOBIOTICS PROJECT

HORIZON EUROPE - MSCA - DN- 2021 #101072780

01-02-2023 to 31-01-2027

#### RAFAEL JIMÉNEZ RIOBOO, CEA/ UNIVERSITY OF PARIS-SACLAY

supervised by Dr. Grégory Pieters

The fact that we PhD Students will be able to work in an interdisciplinary environment, giving us an opportunity to closely work with industry and academia.





ALFONSO FUMANALI DOCIN, CEA/ UNIVERSITY OF PARIS-SACLAY supervised by <u>Dr. Simon SPECKLIN</u>

For me, the main strength of the ISOBIOTICS project is its organization. The goals are very well defined and there is a general idea of how to get there. In addition, the final objectives could be very beneficial for many people, so it is a project with a lot of potential and possibilities for success.

#### MALAMATENIA PAPAVASILEIOU, IMM LISBON/FFUL

supervised by **Prof Gonçalo Bernardes** 

One of the strengths of the ISOBIOTICS project is the collaboration of international and interdisciplinary groups of highly skilled scientists aiming to provide more efficient biotherapeutic proteins.



#### MARC SAN JOSÉ GRACIA, SANOFI AVENTIS DEUTSCHLAND GMBH/ IQS

supervised by Dr. Anna SIB



The noted experience from the Beneficiaries in Isotope Chemistry makes this program an opportunity to develop broad and specific skills in radiochemistry, organic chemistry and medicinal chemistry. The continuous training plus the yearly meetings add value to the PhD consortium since it creates an educational atmosphere where you can share information and experiences with your network. Besides, it has a focus on developing generic skills like critical thinking, team-working, dissemination, which will contribute to our future careers. From carrying out innovative research applied on challenges without straightforward answers, to receive tailored formation and advices, this doctoral network stands out from the rest.

#### TOBIAS FUNDER, ASTRAZENECA STOCKHOLM / KAROLINSKA INSTITUTE

supervised by **Prof Magnus Schou** 

I think its foremost its people as well as the close cooperation of European companies and academic institutions for a common goal.





DAVIDE GUGLIELMINOTTI, LMU/ LUDWIG MAXIMILIAN UNIVERSITY OF MUNICH

supervised by Prof Thomas Carell

The versatility of isotopes in developing traceable molecules.

# HAVE A QUESTION ON YOUR MIND?

Let's Get Connected for Our Latest News & Updates!



https://www.isobiotics-project.org/



https://twitter.com/ISOBIOTICSeuDN



https://www.linkedin.com/groups/9363061/



isobiotics.project@gmail.com

## Don't hesitate to ask everything about us!



Coordination and Management Team (CEA-Saclay/SCBM)





01-02-2023 to 31-01-2027



Dr. Christophe
DUGAVE
(Coordinator)



Mrs. Shivani
UTEKAR
(Project Manager)

Isotopic Labeling & Bio-Organic Chemistry Unit

Institute Frederic Joliot Fundamental Research Division

French Atomic Energy and Alternative Energies Commission (CEA) Building 547 – CEA-Saclay

91191 Gif-sur-Yvette - France

HORIZON EUROPE - MSCA - DN- 2021 #101072780

